I
Imvaq Therapeutics
An innovative cancer immunotherapy company
About Imvaq Therapeutics
Imvaq Therapeutics is a clinical-stage biotechnology company focused on developing viral-based immunotherapies for various cancers. Founded in 2018 by CEO Dr. John Choi and researchers from Memorial Sloan Kettering Cancer Center (MSK), the firm is headquartered in New York City. The company's core mission is to engineer and arm immune-stimulating viruses to combat a range of solid tumors, including challenging cancers like triple-negative breast cancer, skin cancers, and sarcoma.
The company's primary technology is its Vaccinia Immunotherapy Platform (VIP)™, which utilizes both oncolytic and non-oncolytic Modified Vaccinia Ankara (MVA) virus strains. A key feature of the VIP platform is its large capacity for transgene insertion, which allows the viruses to be "armed" with multiple immunostimulatory molecules to enhance the anti-tumor response. Imvaq has also developed a proprietary screening process to identify and remove viral genes that suppress the immune system, aiming to increase therapeutic effectiveness. Its lead product candidate, MQ710, is a second-generation immunotherapy based on an armed MVA virus.
Imvaq's business model centers on the research and development of these novel therapies, with the goal of advancing them through clinical trials and eventually to market. The company operates within the competitive immuno-oncology sector, targeting a critical need for more effective treatments for metastatic solid tumors. To finance its operations, Imvaq has successfully raised significant capital. After a Series A round of $10M in July 2017, the company secured a $15 million Series B financing round in September 2020, led by Hanne Capital. This brought its total raised capital to over $25 million, which was earmarked to fund the Investigational New Drug (IND) application and Phase 1 clinical trials for MQ710, as well as to advance other pipeline assets. However, according to some sources, the company's operational status was listed as "Out of Business" as of June 2024.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Sep 2020 | $15M | $60M | Hanne Capital | — |
| SERIES AEquity / VC | Jul 2017 | $10M | $40M | Undisclosed | — |
Growth signals
Latest recorded traffic for Imvaq Therapeutics is 270 monthly website visits. Imvaq Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Imvaq Therapeutics in the New York City ecosystem
The Imvaq Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Hanne Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Imvaq Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Imvaq Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









